Liver cancer, particularly hepatocellular carcinoma (HCC), remains a leading cause of cancer mortality worldwide. Tumor evolution in HCC is driven by both chromosomal instability (CIN) and epigenetic dysregulation. DNA damage response (DDR) pathways are tightly linked to CIN and to metabolic changes such as a shift towards glycolysis that can follow mitochondrial dysfunction. Recent evidence ties DDR and genotoxic stress to activation of innate immune pathways (for example, the cGAS–STING pathway), type I interferon production, and chemokine-driven immune cell recruitment. Conversely, chronic DNA damage can drive upregulation of immune checkpoint molecules such as PD-L1, promoting immune escape. Given the established connections among histone methylation, DDR, and immune regulation, the authors investigated the role of the H3K36 demethylase KDM2A in liver cancer biology and tumor immunogenicity.
KDM2A is a JmjC-domain histone demethylase with a ZF-CxxC DNA-binding domain that targets unmethylated CpG islands and preferentially demethylates H3K36me2. Prior reports on KDM2A in cancer are heterogeneous, with evidence implicating it in tumor-promoting processes in several cancer types, and limited data suggesting associations with poor prognosis in HCC. This study was designed to test whether KDM2A modulates mitochondrial function, genomic stability, chromatin states, and antitumor immunity in liver cancer models and human tumors.
The authors used genetic silencing of KDM2A in vitro and in vivo to probe its function. They assessed mitochondrial function, cellular redox balance, and genomic stability, and performed transcriptomic and epigenomic analyses focused on immune pathways and distribution of H3K36me2. Immune infiltration was evaluated in human HCC samples and in syngeneic mouse tumor models. The provided source text summarizes the experimental approaches and endpoints but does not include full methodological details, quantitative results, or raw datasets; those elements are not reported here.
Genetic ablation or silencing of KDM2A induced mitochondrial impairment in liver cancer cells, accompanied by perturbation of redox homeostasis. These mitochondrial defects correlated with accumulation of DNA damage, indicating a link between KDM2A activity, mitochondrial integrity, and genomic stability. The observed DNA damage provided a mechanistic bridge to innate immune sensing pathways implicated in recognition of cytosolic DNA and micronuclei.
Following KDM2A loss, cells exhibited activation of innate immune signaling cascades and downstream transcriptional programs. Genotoxic stress and accumulated DNA damage activated pathways that can include cGAS–STING signaling and type I interferon responses, promoting expression of chemokines and cytokines that potentiate immune recruitment. Concomitantly, adaptive immune pathways were engaged, with transcriptional changes consistent with enhanced antigen presentation and T-cell attracting signals.
Loss of KDM2A reshaped the genomic distribution of H3K36me2, particularly at loci regulating chemokine signaling, metabolic pathways, and T-cell recruitment. This epigenetic reprogramming correlated with altered expression of genes implicated in immune communication and metabolic regulation, supporting a model in which KDM2A controls tumor immunogenicity through direct chromatin-level modulation of immune- and metabolism-related gene networks.
Analysis of human liver tumors showed that high KDM2A expression associated with poorer histological differentiation, enrichment of macrophages, and exclusion of CD8⁺ T cells, describing an immune-excluded tumor phenotype. These clinical correlations align with the mechanistic data indicating that KDM2A activity fosters an immunosuppressive microenvironment and restricts cytotoxic T-cell access to the tumor.
In immunocompetent syngeneic mouse models, genetic loss of KDM2A increased intratumoral infiltration of CD8⁺ T cells, validating that KDM2A modulation can alter the tumor immune microenvironment in vivo. These findings provide functional evidence that KDM2A impacts antitumor immune responses beyond cell-intrinsic effects.
Taken together, the data position KDM2A as a multifunctional regulator that integrates mitochondrial health, genomic stability, epigenetic state (H3K36me2), and immune evasion in liver cancer. The authors propose that targeting KDM2A could increase tumor immunogenicity and enhance responses to immunotherapies such as immune checkpoint blockade. This approach would aim to convert immune-excluded tumors into more inflamed, T-cell–infiltrated states conducive to therapeutic immune activation.
The presented summary is limited to the information provided in the source text. Specific experimental parameters (for example, exact genetic constructs or knockdown approaches, sample sizes, quantitative effect sizes, statistical analyses, and experimental replicates), raw data, and procedural details from the Materials and Methods and Results sections were truncated in the provided source excerpt and therefore are not reported here. Readers should consult the full published article for comprehensive methods, quantified results, figures, and supplementary data.
The study identifies KDM2A as a key epigenetic regulator in liver cancer that maintains mitochondrial function and genome stability while suppressing innate and adaptive immune activation through chromatin-mediated control of immune- and metabolism-related genes. KDM2A ablation produces mitochondrial dysfunction and DNA damage that activate innate immune sensing and chemokine programs, leading to increased CD8⁺ T-cell infiltration in preclinical models. Clinical correlations in human HCC samples further support the association between high KDM2A expression and an immune-excluded, less-differentiated tumor phenotype. Targeting KDM2A is proposed as a potential strategy to enhance tumor immunogenicity and improve immunotherapy responses; however, full methodological and quantitative details are available only in the complete article.